Precision oncology: separating the wheat from the chaff

被引：31
|
作者：
Remon, Jordi [1 ]
Dienstmann, Rodrigo [2 ]
机构：
[1] HM Delfos, Ctr Integral Oncol Clara Campal Barcelona, Med Oncol Dept, Barcelona, Spain
[2] Hosp Valle De Hebron, Oncol Data Sci ODysSey Grp, Barcelona, Spain
来源：
ESMO OPEN | 2018年 / 3卷 / 06期
关键词：
CELL LUNG-CANCER; METASTATIC BREAST-CANCER; OPEN-LABEL; MOLECULAR CHARACTERIZATION; ANTICANCER DRUGS; TARGETED THERAPY; FDA APPROVAL; SOLID TUMORS; PHASE-II; MEDICINE;
D O I：
10.1136/esmoopen-2018-000446
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Precision oncology based on next-generation sequencing (NGS) test is growing in daily clinical practice. However, the real impact of this strategy in patients' outcome on a large scale remains uncertain. In this review, we summarise existing literature on this topic, limitations for broad NGS implementation, bottlenecks in genomic variant interpretation and the role of molecular tumour boards.
引用
收藏
页数：7
相关论文
共 50 条
12345